IMMU-47. RNA-NANOPARTICLE VACCINES ARE SAFE AND IMMUNOLOGICALLY ACTIVE IN CLIENT-OWNED CANINES WITH TERMINAL GLIOMAS

BACKGROUND: The lack of appropriate preclinical murine glioblastoma models limits comprehensive toxicity/efficacy evaluation of investigational agents. To overcome this challenge, we evaluated the safety and activity of a new immunotherapeutic technology that we have pioneered (composed of tumor mRN...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuro Oncol
Prif Awduron: Carrera-Justiz, Sheila, Stover, Brian, Milner, Rowan, Weidert, Frances, Huang, Jianping, Mitchell, Duane, Mendez-Gomez, Hector, Sayour, Elias
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2019
Pynciau:
Immunology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847721/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.539
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg